Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Turkish Trial
View:
Post by Viking2233 on Mar 06, 2024 9:46am

Turkish Trial

Well we missed the February deadline for first dosing and not one word or update from management. This trial was initially scheduled to commence in the fall of 2023 with first dosing, then moved to Feb 2024. We are now at March 6 and no first dosing announced.

They have had 10 weeks to recruit patients but have yet to announce first dosing. If it takes this long to find one suitable patient, how long will it take to recruit 150 or 260?? Based on using the current math it would take 2600 weeks, thats 50 years. Now of course that is not realistic but just to prove a point.

Now of course we need to be selective and identify the best patients to insure a successful trial. I get all that and of course we dont want to rush the recruiting and select the wrong patients.

My opinion here is they have not finalized the Turkish sites and doctors and in fact recruitment has been delayed until they finalize the sites. This is the only logical reason I can think of.

It is frustrating and disappointing in the delays considering this trial has been in the planning stages for 2 years. When you couple the fact that management has not updated the markets just intesifys the frustration.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities